Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
7 Hills Pharma, LLC
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06362369CT.gov A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | — | Recruiting | — | — | — |
NCT06514651CT.gov MAQ-001 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05933265CT.gov Study of LP-184 in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05533697CT.gov Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05407675CT.gov A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04940299CT.gov Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04855929CT.gov A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. | — | Completed | — | — | — |
NCT04319224CT.gov Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors | — | Terminated | — | — | — |
NCT03816345CT.gov Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | — | Recruiting | — | — | — |
NCT03989362CT.gov Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer | — | Completed | — | — | — |
Show 31 more trialsShow fewer
NCT03752398CT.gov A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | — | Completed | — | — | — |
NCT03461952CT.gov Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) | — | Terminated | — | — | — |
NCT03459222CT.gov An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT03335540CT.gov An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | — | Completed | — | — | — |
NCT03449108CT.gov LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | — | Active Not Recruiting | — | — | — |
NCT03444753CT.gov An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed | — | Terminated | — | — | — |
NCT03297606CT.gov Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | — | Recruiting | — | — | — |
NCT03400332CT.gov A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | — | Completed | — | — | — |
NCT03525795CT.gov ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03369223CT.gov A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT03241173CT.gov A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | — | Completed | — | — | — |
NCT03251924CT.gov A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03203876CT.gov A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03110107CT.gov First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03126110CT.gov Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | — | Completed | — | — | — |
NCT02996110CT.gov A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
NCT02834013CT.gov Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | — | Active Not Recruiting | — | — | — |
NCT02904226CT.gov JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | — | Completed | — | — | — |
NCT02737475CT.gov An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT02668770CT.gov Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT02750514CT.gov An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02675439CT.gov Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | — | Terminated | — | — | — |
NCT02658890CT.gov An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT02693535CT.gov TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | — | Recruiting | — | — | — |
NCT02453620CT.gov Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02496208CT.gov Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | — | Active Not Recruiting | — | — | — |
NCT01986426CT.gov LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | — | Completed | — | — | — |
NCT01988077CT.gov Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients | — | Terminated | — | — | — |
NCT01750580CT.gov Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor | — | Completed | — | — | — |
NCT01714739CT.gov A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00060372CT.gov Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | 7 Hills Pharma, LLC | P2 | BB · 65 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →